Onconetix, Inc. 8-K/A

What Happened Onconetix, Inc. (ONCO) announced that the Board appointed David White as Chief Executive Officer effective March 18, 2026. Karina Fedasz will remain Interim Chief Financial Officer. The Compensation Committee reduced Ms. Fedasz’s monthly compensation by $5,000 and Lead Independent Director Andrew Oakley’s monthly compensation by $26,000, both effective March 18, 2026. On March 19, 2026, director Timothy Ramdeen resigned from the Board and its committees (not due to any disagreement with management), and the Board appointed Sammy Dorf to the Board and the Audit Committee effective that same date.

Key Details

• David White appointed CEO effective March 18, 2026; monthly base salary of $21,700 per his employment agreement.
• Mr. White’s agreement includes non‑compete, confidentiality and non‑solicit covenants; the employment agreement is filed as Exhibit 10.1 (certain portions redacted).
• Compensation adjustments effective March 18, 2026: Karina Fedasz −$5,000/month; Andrew Oakley −$26,000/month.
• Board changes effective March 19, 2026: Timothy Ramdeen resigned; Sammy Dorf joined the Board and Audit Committee. Company states no related-party transactions or family relationships involving the new appointees.

Why It Matters A new full‑time CEO and concurrent pay adjustments are material governance and leadership developments that can affect strategy, execution and operating costs. The appointment of Sammy Dorf to the Audit Committee and the resignation of an existing director change Board oversight composition. Investors should note the CEO’s compensation, the non‑compete/confidentiality covenants in his agreement, and that the company filed the employment agreement with limited redactions (available to the SEC on request). These are governance and leadership facts to monitor for their potential impact on corporate direction and investor confidence.